Home/Pipeline/BHV-5000 (NMDA antagonist)

BHV-5000 (NMDA antagonist)

Major Depressive Disorder (MDD)

Phase 1Completed

Key Facts

Indication

Major Depressive Disorder (MDD)

Phase

Phase 1

Status

Completed

Company

Biohaven

About Biohaven

Biohaven is a neuroscience-focused biopharmaceutical company with a diversified portfolio of clinical-stage and commercial assets. Following the spin-off of its migraine franchise to Pfizer in 2022, the 'New Biohaven' is advancing a next-generation pipeline targeting neurodegenerative diseases, movement disorders, and neuropsychiatric conditions. The company leverages multiple scientific platforms, including its proprietary glutamate modulation and myostatin inhibition technologies, to address complex neurological disorders with significant market potential.

View full company profile

Therapeutic Areas

Neurology Neuropsychiatry Neuromuscular Oncology

Other Major Depressive Disorder (MDD) Drugs

Drug	Company	Phase	Status
XEN1101	Xenon Pharmaceuticals	Phase 3	Active
Undisclosed CNS Candidate	Alto Neuroscience	Phase 1	Active
Navacaprant (NMRA-140)	Neumora Therapeutics	Phase 3	Active
MW-101	MindWalk Holdings	Phase 2	Active, recruiting
NPH-101	Neuphoria Therapeutics	Phase 2	Active
Itruvone (PH10)	Vistagen Therapeutics	Phase 2	Active